Your browser doesn't support javascript.
loading
Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.
Gonzalez, Rafael; Havrilesky, Laura J; Myers, Evan R; Secord, Angeles Alvarez; Dottino, Joseph A; Berchuck, Andrew; Moss, Haley A.
Afiliação
  • Gonzalez R; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, United States of America; Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, United States of America. Electronic address: rafael.gonzalez@duke.edu
  • Havrilesky LJ; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, United States of America; Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, United States of America.
  • Myers ER; Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, United States of America.
  • Secord AA; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, United States of America; Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, United States of America.
  • Dottino JA; Division of Surgery, Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, TX, United States of America.
  • Berchuck A; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, United States of America; Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, United States of America.
  • Moss HA; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, United States of America; Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, United States of America.
Gynecol Oncol ; 159(2): 483-490, 2020 11.
Article em En | MEDLINE | ID: mdl-32863036
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Temas: ECOS / Aspectos_gerais / Financiamentos_gastos Bases de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Biomarcadores Tumorais / Quimioterapia de Manutenção / Inibidores de Poli(ADP-Ribose) Polimerases / Carcinoma Epitelial do Ovário Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Limite: Female / Humans Idioma: En Revista: Gynecol Oncol Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Temas: ECOS / Aspectos_gerais / Financiamentos_gastos Bases de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Biomarcadores Tumorais / Quimioterapia de Manutenção / Inibidores de Poli(ADP-Ribose) Polimerases / Carcinoma Epitelial do Ovário Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Limite: Female / Humans Idioma: En Revista: Gynecol Oncol Ano de publicação: 2020 Tipo de documento: Article